Cited 124 times in
Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 심효섭 | - |
dc.contributor.author | 이창영 | - |
dc.contributor.author | 조병철 | - |
dc.contributor.author | 차윤진 | - |
dc.date.accessioned | 2017-02-27T08:15:03Z | - |
dc.date.available | 2017-02-27T08:15:03Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/147129 | - |
dc.description.abstract | INTRODUCTION: PD-L1 expression is a predictive biomarker for response to anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors and can be evaluated by immunohistochemistry. Results of the clinicopathologic characteristics of PD-L1-positive lung adenocarcinoma have been inconsistent in previous studies, and there are no reports on the relationship between PD-L1 expression and p53 status in lung adenocarcinoma. METHODS: We examined PD-L1 and p53 expression in a total of 323 surgically resected lung adenocarcinoma cases using anti-PD-L1 (clone SP142) and anti-p53 (clone DO-7) antibodies, and analyzed the clinicopathologic characteristics of PD-L1-positive cases and their relationship with p53 status. RESULTS: PD-L1 expression in tumor cells was positive in 60 of 323 cases (18.6%). Higher PD-L1 expression (≥50%) was more prevalent in former or current smokers (p=0.026) and was associated with more pack-years (p=0.016). PD-L1-positive tumors were significantly associated with solid predominant type (p<0.001), p53 aberrant expression (p<0.001), and PD-L1 expression in tumor-infiltrating immune cells (p<0.001). Patients with stage I to III tumors harboring PD-L1-positive tumor cells showed poor recurrence-free survival (p<0.001) and overall survival (p<0.001) on univariate analysis. CONCLUSIONS: PD-L1 expression in tumor cells, solid predominant histology, p53 aberrant expression, and PD-L1 expression in tumor-infiltrating immune cells are closely related. These variables should be considered when analyzing the clinical outcomes of patients with lung adenocarcinomas treated with anti-PD1/PD-L1 immune checkpoint inhibitors. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.format.extent | 73~80 | - |
dc.language | English | - |
dc.publisher | Elsevier Scientific Publishers | - |
dc.relation.isPartOf | LUNG CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenocarcinoma/metabolism* | - |
dc.subject.MESH | Adenocarcinoma/mortality | - |
dc.subject.MESH | Adenocarcinoma/pathology* | - |
dc.subject.MESH | Adenocarcinoma/surgery | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | B7-H1 Antigen/metabolism* | - |
dc.subject.MESH | Biomarkers, Tumor/metabolism | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genes, erbB-1/genetics | - |
dc.subject.MESH | Genes, p53/immunology* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunotherapy | - |
dc.subject.MESH | Lung Neoplasms/metabolism* | - |
dc.subject.MESH | Lung Neoplasms/mortality | - |
dc.subject.MESH | Lung Neoplasms/pathology* | - |
dc.subject.MESH | Lung Neoplasms/surgery | - |
dc.subject.MESH | Lymphocytes, Tumor-Infiltrating/metabolism | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Molecular Targeted Therapy | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Protein-Tyrosine Kinases/genetics | - |
dc.subject.MESH | Proto-Oncogene Proteins/genetics | - |
dc.subject.MESH | Proto-Oncogene Proteins p21(ras)/genetics | - |
dc.subject.MESH | Receptor Protein-Tyrosine Kinases/genetics | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Smoking/epidemiology | - |
dc.title | Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. | - |
dc.type | Article | - |
dc.publisher.location | Ireland | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Yoon Jin Cha | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Chang Young Lee | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Hyo Sup Shim | - |
dc.identifier.doi | 10.1016/j.lungcan.2016.05.001 | - |
dc.contributor.localId | A04001 | - |
dc.contributor.localId | A01166 | - |
dc.contributor.localId | A02219 | - |
dc.contributor.localId | A03245 | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J02174 | - |
dc.identifier.eissn | 1872-8332 | - |
dc.identifier.pmid | 27237031 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0169500216303130 | - |
dc.subject.keyword | Adenocarcinoma | - |
dc.subject.keyword | Cancer immunotherapy | - |
dc.subject.keyword | Lung cancer | - |
dc.subject.keyword | PD-L1 | - |
dc.subject.keyword | p53 | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.alternativeName | Shim, Hyo Sup | - |
dc.contributor.alternativeName | Lee, Chang Young | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.alternativeName | Cha, Yoon Jin | - |
dc.contributor.affiliatedAuthor | Cha, Yoon Jin | - |
dc.contributor.affiliatedAuthor | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | Shim, Hyo Sup | - |
dc.contributor.affiliatedAuthor | Lee, Chang Young | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.citation.volume | 97 | - |
dc.citation.startPage | 73 | - |
dc.citation.endPage | 80 | - |
dc.identifier.bibliographicCitation | LUNG CANCER, Vol.97 : 73-80, 2016 | - |
dc.date.modified | 2017-02-24 | - |
dc.identifier.rimsid | 47160 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.